New Studies Published Comparing BIO 300 to Neulasta® for Acute Radiation Syndrome

MINNEAPOLIS--(BUSINESS WIRE)--A recently published paper in the International Journal of Radiation Biology details results from a series of studies conducted with Humanetics Corporation’s (Humanetics) new radioprotective drug, BIO 300. In collaboration with researchers at the Uniformed Services University of the Health Sciences, within the United States Department of Defense (DoD),...

Click to view original post